The Relationship Between Pericardial Fat Thickness and Arterial Stiffness in HFpEF Patients
1 other identifier
observational
200
1 country
1
Brief Summary
Heart failure with preserved ejection fraction (HFpEF) was considered as a heterogeneous disease with multi-organ and multi-system design, which is related to various complications, such as hypertension, obesity and arteriosclerosis. Studies have found that hypertension and obesity are respectively associated with increased arterial stiffness. However, there is still no research investigating the the relationship between blood pressure and arterial stiffness in HFpEF patients with different levels of obesity.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2020
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2020
CompletedFirst Submitted
Initial submission to the registry
October 15, 2020
CompletedFirst Posted
Study publicly available on registry
October 20, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 20, 2022
CompletedOctober 20, 2020
October 1, 2020
2.2 years
October 15, 2020
October 15, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Arterial stiffness
The arterial stiffness of HFpEF patients, for example brachial ankle pulse wave velocity, ardioankle vascular index and so on.
On admission
Epicardial Fat Tissue
Epicardial Fat Tissue by cardiac color Doppler ultrasound
On admission
Eligibility Criteria
Heart failure patients with preserved ejection fraction (HFpEF)
You may qualify if:
- Adult aged \>=18years old;
- Diagnosed with HFpEF.
- Diagnostic criteria including:
- left ventricular ejection fraction ≥50%;
- with the symptoms and/or signs of heart failure;
- BNP≥35 pg/mL and/or NTproBNP≥125 pg/mL;
- at least one additional criterion: relevant structural heart disease(LVH and/or LAE) or diastolic dysfunction
You may not qualify if:
- LVEF less than 45% at any time;
- Severe liver failure;
- Primary pulmonary hypertension;
- Age \<18 years old.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The First Affiliated Hospital of Chongqing Medical University
Chongqing, China
Study Officials
- STUDY DIRECTOR
Dongying Zhang, doctor
First Affiliated Hospital of Chongqing Medical University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Clinical Professor
Study Record Dates
First Submitted
October 15, 2020
First Posted
October 20, 2020
Study Start
September 1, 2020
Primary Completion
December 1, 2022
Study Completion
December 20, 2022
Last Updated
October 20, 2020
Record last verified: 2020-10
Data Sharing
- IPD Sharing
- Will not share